We're spending heavily to take the same mechanism of action, which we have in every cancer cell line we've tried. We're now taking it from g b m on small salung, pancreatic, overian, brain tastices, liver, gastric. So it really is a clinical development programme where the n is 20 to 30 times where we are to day. And then to spread into these much larger cancers,. so non small canser, 200 thousand pancreatic, forty thousand, ovarian, ultimately breast, through development. Back to the biotex side of a great drug: These can be fabulous businesses, but the next break through is the next drug. In our case,

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode